AI-based measurement of tumor burden in prostate cancer using PET-CT scans
The Prognostic Value of AI-based Measurements of Tumour Burden in PSMA PET-CT in Patients With Prostate Cancer
This study is testing a new AI method to see how well it can measure tumor size in prostate cancer patients using special PET-CT scans to help understand their chances of survival.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 20 Years to 120 Years |
| Sex | Male |
| Sponsor | Skane University Hospital Academic / other |
| Locations | 2 sites (Lund and 1 other locations) |
| Trial ID | NCT06363435 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of an AI-based method for automatically calculating tumor burden in prostate cancer patients using 18F-PSMA-1007 PET-CT scans. The study will measure tumor volume and uptake in various locations, including the prostate, pelvic lymph nodes, distant lymph nodes, and bones. Patients referred for either initial staging of high-risk prostate cancer or due to biochemical recurrence will be included. The data collected will be analyzed over a five-year follow-up period to assess its correlation with overall survival and progression-free survival.
Who should consider this trial
Good fit: Ideal candidates for this study are men diagnosed with high-risk prostate cancer who are referred for a clinically indicated 18F-PSMA-1007 PET-CT scan.
Not a fit: Patients under 20 years old will not benefit from this study as they are excluded from participation.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of tumor burden assessment, leading to improved treatment strategies and outcomes for prostate cancer patients.
How similar studies have performed: While the use of AI in medical imaging is gaining traction, this specific approach to measuring tumor burden in prostate cancer using PSMA PET-CT scans is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients referred to a clinically indicated 18F-PSMA-1007 PET-CT scan at Skåne University Hospital, Lund or Malmö, Sweden Exclusion Criteria: * Patients under 20 years old
Where this trial is running
Lund and 1 other locations
- Skåne University Hospital — Lund, Sweden (Recruiting)
- Skåne university hospital — Malmö, Sweden (Recruiting)
Study contacts
- Study coordinator: Elin Tragardh, Prof
- Email: elin.tragardh@skane.se
- Phone: +4640338724
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.